Google, Cochlear harness AI to help people hear again
Peter Jackson used AI to reveal ‘secret’ conversations between The Beatles in the Get Back documentary. Cochlear and Google plan to bring that technology to those hard of hearing.
Cochlear
‘Sensible’ workers know the risks of bumper wage rises
Cochlear boss Dig Howitt says its wage bill hasn’t risen in line with inflation and employees understand the economics at play, as Philip Lowe issues a stern warning about big pay rises.
Banks push ASX to biggest fall in six weeks
Bourse at four-week low. CBA margins prompt selling of banks. Corporate Travel, Treasury Wine dives on misses. Cochlear jumps on buyback. Star rockets 14 per cent.
Journal sings Kazia anti-cancer drug’s praises
The potential of Kazia Therapeutics’ cancer-fighting drug EVT801 has been hailed in a scientific journal, as the company runs a clinical trial.
ASX ends up 1pc; miners gain as energy stocks slip
ASX closes at seven-month high. Warrego gives Beach Energy five days to match Hancock’s ‘superior’ offer, iron ore posts record monthly rise and Woodside leads energy losses.
Notable success in medical technology
Medical technology and medical devices is an advanced area of research, development and manufacturing in which Australia has a strong record.
Gathering seeks change of climate in China relations
Executives from a host of Australian and Chinese companies will meet in Canberra next week to discuss ways to use climate change to boost business ties with China.
Nation’s biggest health companies vow to cut carbon footprint
Australia’s biggest health companies are launching a range of strategies to cut carbon emissions, saying environmental goals are “inextricably linked” to healthcare.
Love Island and The Simpsons – how Cochlear will lift its profit 10pc this year
Hearing implants are becoming more mainstream, even featuring on The Simpsons and Love Island. Cochlear CEO Dig Howitt plans to ride the wave.
Medical device stocks that could soar from tailwinds
With strong tailwinds behind them, medical devices stocks are ready to reach new heights. Here’s why they’re set for healthy profits.
Cochlear takes long-term view on China
Hearing implant giant Cochlear is pressing ahead with its China’s plant despite increasing tensions between Canberra and Beijing.
ASX drops; Costa, Cochlear rally in bleak session
ASX led lower by tech and discretionary stocks. Nanosonics falls on profit slump, Cochlear and Costa leap of earnings, Coles profit dips and Tyro sell off continues.
Biotechs applaud tax cut move to keep Aussie research
The federal government’s ‘patent box’ will almost halve the tax rate on Australian research that is commercialised locally.
ASX200 ends down 0.1% as banks, miners slip
The S&P/ASX 200 finished slightly weaker after a late retreat, with the big banks and miners in the red after mixed leads from Wall Street.
Vaccination not the only sharemarket challenge
Bond yields rising, stimulus programs running out – the risks are out there for sharemarket investors.
ASX ends lower as Evergrande falls
Australia’s sharemarket fell slightly at the end of a volatile week. The S&P/ASX 200 index closed down 0.4% at 7342.6 and suffered its first three-week fall in seven months.
ASX recovers to end flat, RBA holds rates
The ASX recovered to finish steady after the RBA said the economy will ‘bounce back’ from Delta. Iron ore prices tumbled.
How Cochlear helped ‘Hulk’ hear again
Face masks are annoying but they delivered Cochlear an unexpected uplift during the global pandemic.
ASX falls 5 days in a row, Cochlear drops
ASX 200 closes slightly lower. Iron ore futures rising. Cochlear guidance disappoints, Sydney Airport losses deepen, Stockland shares down.
We’re all ears: tech plan wins over business
Bionic ear maker Cochlear has backed Josh Frydenberg’s ‘patent box’’ tax break for innovation predicting it could create more highly paid jobs in Australia.
Improving safety of bionic devices
Physicists at the University of Sydney have developed a new method of testing if bionic devices are leak-proof.
Cochlear holds back some JobKeeper cash
Cochlear’s boss Dig Howitt has defended the company’s decision to hold to $10.4m of JobKeeper money.
Company holds firm on JobKeeper
A medical pioneer company pressured over JobKeeper has pledged to pay some of it back but not all, saying it was used as intended.
ASX hits 3-week low
ASX closes at three-week low, spurred on by a downturn in US futures.
ASX higher as Afterpay jumps but miners drag
Stocks closed higher, with Afterpay and Cochlear starring, and ahead of Joe Biden outlining his economic plan.
‘Lead the way in innovation’
Telehealth solutions must be a routine part of a modern healthcare system, says Cochlear chief Dig Howitt.
Cochlear boss likes sound of new CSL plant
Cochlear’s CEO Dig Howitt says the federal government’s $1.8bn deal with CSL will build Australia’s competitive advantage in medical manufacturing.
Biotech taps Bosch to automate Covid test factory
Bosch Australia is undergoing a renaissance, returning to turning over $1bn a year and providing factory automation to Australia’s biggest medical companies.
Howitt beats a hasty retreat from China group
Cochlear CEO Dig Howitt couldn’t get off Australia’s new China foundation fast enough.
‘We’re looking for the next Apple’
Good design is more than just aesthetics, it goes to the core of the success.
Original URL: https://www.theaustralian.com.au/topics/cochlear/page/2